Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences reported that the U.S. FDA has accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma and has set a PDUFA goal date of April 14, 2027.
The BLA is backed by the registrational ChonDRAgon study, where ozekibart cut the risk of disease progression or death by 52% versus placebo (hazard ratio 0.479) and more than doubled median progression-free survival to 5.52 months vs 2.66 months. Disease control rate and pain and function measures also favored ozekibart.
If approved, ozekibart would be Inhibrx’s first commercial product and the first FDA‑approved systemic therapy for this cancer. The drug showed a generally manageable safety profile, with hepatotoxicity mitigated through patient selection and close monitoring.
Inhibrx Biosciences director Kristiina Vuori, MD, received a grant of stock options for 15,000 shares of common stock. The options have an exercise price of $95.22 per share, become fully exercisable on June 3, 2027, subject to her continued service, and expire on June 3, 2036.
Inhibrx Biosciences, Inc. director Jon Faiz Kayyem received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $95.2200 per share and become fully exercisable on June 3, 2027, subject to his continued service.
The options expire on June 3, 2036. Following this award, Kayyem holds 15,000 derivative securities (stock options) directly. This is a compensation-related grant, not an open‑market purchase or sale of shares.
Inhibrx Biosciences, Inc. director Douglas Forsyth received a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $95.22 per share and expire on June 3, 2036.
According to the filing, the stock option will become fully exercisable on June 3, 2027, subject to Forsyth’s continued service through that date. Following this award, he holds 15,000 stock options directly, and the transaction reflects compensation rather than an open‑market purchase or sale.
Inhibrx Biosciences, Inc. director Kimberly Manhard received a grant of stock options covering 15,000 shares of common stock. The options carry an exercise price of $95.22 per share and will be fully exercisable on June 3, 2027, subject to her continued service through that date.
Following this grant, she holds stock options for 15,000 underlying shares directly. This award is compensation-related and was not an open-market purchase or sale of existing shares.
Inhibrx Biosciences, Inc. reported results from its 2026 Annual Meeting of Stockholders held online on June 3, 2026. A quorum of 11,541,232 shares was present, representing about 79% of the 14,607,286 common shares entitled to vote as of April 7, 2026.
Stockholders elected Class II directors Douglas G. Forsyth and Kimberly Manhard to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified, or earlier death, resignation, or removal. Forsyth received 7,608,469 votes for and 1,463,474 withheld, with 2,469,289 broker non-votes. Manhard received 9,035,097 votes for and 36,846 withheld, with 2,469,289 broker non-votes.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 11,510,478 votes for, 30,347 against, and 407 abstentions.
Inhibrx Biosciences, Inc. Schedule 13G/A amendment reports beneficial ownership by Viking Global affiliated entities and related persons and removes David C. Ott as a reporting person effective March 31, 2026. The filing lists aggregate beneficial ownership positions and discloses a Warrant exercise limiter (the "Blocker").
The filing states that Viking Global Investors LP and affiliated entities may be deemed to beneficially own up to 1,461,633 shares (representing 9.99% of the class) based on 14,607,036 shares outstanding as of March 11, 2026, and details component holdings among VGOP, KAVRA 104, VGOD and related GPs.
INHIBRx Biosciences filed an amendment to a Schedule 13G/A reporting shared beneficial ownership of 1,461,105 shares, equal to 9.99% of common stock. The filing states there were 14,607,286 shares outstanding as of April 7, 2026 and that the Reporting Persons assume exercise of Pre-Funded Warrants for 18,398 shares when calculating ownership. The Master Fund directly holds 1,442,707 shares and 732,157 pre-funded warrants exercisable at $0.0001 per share, subject to a Beneficial Ownership Limitation that caps aggregate exercises to not more than 9.99%. Perceptive Advisors is the investment manager and Joseph Edelman is the managing member; both are reported as beneficial owners by attribution.
Inhibrx Biosciences, Inc. reported first quarter 2026 results, showing a narrower net loss and a stronger cash position alongside higher debt and a stockholders’ deficit. Net loss was $33.4 million, or $2.15 per share, compared to $43.3 million, or $2.80 per share, in the first quarter of 2025.
Research and development expenses fell to $25.2 million, and general and administrative costs were broadly stable at $5.7 million. Cash and cash equivalents rose to $161.7 million as of March 31, 2026, supported by $75.0 million of additional loan proceeds, which increased long-term debt to $175.0 million and resulted in a stockholders’ deficit of $21.0 million.
Clinically, the company highlighted updated interim data for INBRX-106 in a randomized Phase 2 HNSCC trial and for ozekibart (INBRX-109) in colorectal cancer. It submitted a Biologics License Application for ozekibart in conventional chondrosarcoma and plans key FDA interactions in the second half of 2026.
Inhibrx Biosciences reported a Q1 2026 net loss of $33.4M, narrowing from $43.3M a year earlier as operating expenses fell. Research and development dropped 32% to $25.2M, mainly from lower chondrosarcoma trial and manufacturing costs, while general and administrative expense was $5.7M.
Cash and cash equivalents were $161.7M as of March 31, 2026, and management believes this will fund operations for at least 12 months, but long‑term debt rose to $175.0M after drawing an additional $75.0M term loan at an effective interest rate of 17.5%.
The pipeline advanced meaningfully. Ozekibart showed encouraging efficacy in colorectal cancer and Ewing sarcoma and has a biologics license application filed for conventional chondrosarcoma after a registrational trial more than doubled median progression‑free survival to 5.52 months. INBRX‑106 delivered higher response rates than pembrolizumab alone in first‑line head and neck cancer, with a Phase 3 HexAgon study planned to start in the third quarter of 2026.